Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys

This article has been Reviewed by the following groups

Read the full article

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2022.05.21.492923: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIACUC: Immunization and challenge of rhesus macaques: All animal studies were approved by the NIAID Animal Care and Use Committee.
    Sex as a biological variableEight juvenile to young adult male Indian-origin rhesus macaques (Macaca mulatta), confirmed to be seronegative for HPIV3 and SARS-CoV-2, were immunized intranasally (0.5 ml per nostril) and intratracheally (1 ml) with a total does of 6.3 log10 plaque-forming units (PFU) of B/HPIV3/S-6P or the empty vector control B/HPIV3.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Infected monolayers were overlaid with culture medium containing 0.8% methylcellulose, and incubated at 32°C for 6 days, fixed with 80% methanol, and immunostained with a rabbit hyperimmune serum raised against purified HPIV3 virions to detect B/HPIV3 antigens, and a goat hyperimmune serum to the secreted SARS-CoV-2 S to detect co-expression of the S protein, followed by infrared-dye conjugated donkey anti-rabbit IRDye680 IgG and donkey anti-goat IRDye800 IgG secondary antibodies (LiCor).
    anti-rabbit IRDye680 IgG
    suggested: None
    anti-goat
    suggested: None
    Dissociation-enhanced lanthanide fluorescent (DELFIA) time resolved fluorescence (TRF) immunoassay, ELISA and live HPIV3 and SARS-CoV-2 neutralization assay: Levels of anti-SARS-CoV-2 S antibodies elicited by B/HPIV3/S-6P were determined by DELFIA-TRF (Perkin Elmer) from NW or BAL following the supplier’s protocol and from serum samples by ELISA (Liu et al., 2021) using the recombinantly-expressed secreted version of S-2P (Wrapp et al., 2020), or a fragment (aa 328-531) containing the receptor binding domain (RBD) of the SARS-CoV-2 S protein (Walls et al., 2020).
    anti-SARS-CoV-2 S
    suggested: None
    The secondary antibodies used in both assays were goat anti-monkey IgG(H+L) horseradish peroxidase (HRP) (Thermo Fisher, Cat #PA1-84631)
    anti-monkey IgG(H+L
    suggested: None
    The antibodies used for extracellular and intracellular staining were: CD69 (FITC, clone FN50, Biolegend)
    CD69
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    African green monkey kidney Vero (ATCC CCL-81) and Vero E6 (ATCC CRL-1586) cells were cultured in Dulbecco’s MEM with GlutaMAX (Thermo Fisher Scientific) with 5% FBS and 1% L-glutamine.
    Vero E6
    suggested: None
    The B/HPIV3/S-6P cDNA was used to transfect BHK21 cells (clone BSR T7/5, stably expressing T7 RNA polymerase (Buchholz et al., 1999)), together with helper plasmids encoding the N, P and L proteins (Buchholz et al., 2004; Liu et al., 2021), to produce the B/HPIV3/S-6P recombinant virus.
    BHK21
    suggested: None
    Briefly, Vero cell monolayers in 24-well plates were infected in duplicate with 10-fold serially diluted samples.
    Vero
    suggested: None
    Recombinant DNA
    SentencesResources
    , luciferase reporter (pHR’ CMV Luc), lentivirus backbone (pCMV ΔR8.2), and human transmembrane protease serine 2 (TMPRSS2) at a ratio of 1:20:20:0.3 into HEK293T/17 cells (ATCC) with transfection reagent LiFect293™.
    pCMV ΔR8.2
    suggested: None
    Standard curves were generated using serially diluted pcDNA3.1 plasmids encoding gN, gE, or sgE sequences.
    pcDNA3.1
    suggested: RRID:Addgene_79663)
    Software and Algorithms
    SentencesResources
    IC50 titers were determined using a log (agonist) vs. normalized response (variable slope) nonlinear function in Prism v8 (GraphPad).
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)
    Data were analyzed using FlowJo version 10.
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)

    Results from OddPub: Thank you for sharing your data.


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04816643RecruitingA Phase 1/2/3 Study to Evaluate the Safety, Tolerability, an…
    NCT00686075CompletedA Study to Evaluate the Safety, Tolerability, Immunogenicity…


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.